Main&Co's office space is now 100 percent leased. Courtesy of Main&Co

Two tech-focused companies moved into a newly developed office space in downtown Houston at the intersection of Main Street and Commerce Street. One company relocated its Houston office, and the other company has expanded to the city for the first time.

Oil and gas AI-enabled analytics platform, Ruths.ai relocated its downtown office to Main&Co, located at 114 Main St. The company has 8,457 square feet of office space in the recently renovated historic building.

Meanwhile, global robotics process automation company UiPath has expanded to build a Houston team. The computer software company is based in New York, but has a presence in 18 countries. The company's office has 5,187 square feet of Main&Co's office space.

The two leases account for 100 percent of the office space in the mixed-use facility, which is owned by Houston-based investment firm, NewForm Real Estate. The company does have 1,136 square foot street-level retail space left yet to rent.

The five-story development completed renovations in the summer of last year and has, in addition to the office space, bars — including The Cottonmouth Club, ETRO Nightclub and Lilly&Bloom — and a contemporary art gallery on the fifth floor called the LCD Gallery.

"Main&Co has become a bustling epicenter of culture, arts, nightlife, and commerce in Downtown Houston," says Dan Zimmerman, president of NewForm Real Estate, in a release. "Restoring these iconic historic buildings and leasing the office space to cutting-edge tech firms is a testament that landmark real estate has a place in the future landscape of our city."

Last week, Greenway Plaza announced three different tech organizations that are moving to or had moved to its office park. Those transactions accounted for over 20,000 square feet of space.

Recently renovated

Courtesy of Main&Co

The renovation of the structure concluded in June of 2018.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”